Beli Lucius Niraparib dalam talian
Beli Lucius Niraparib dalam talian

Beli Lucius Niraparib dalam talian

EUR 173.33

1,000+ vendidos
Preco promocional

Farmacia fisica em Hong Kong, 100% de autenticidade garantida

Destaques do produto

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Garantias de servico

Envio direto internacionalFarmacia autorizadaRevisado por farmaceuticoGarantia de autenticidade

Especificacoes

Especificacao
100mg*30 comprimidos
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong

10000 em stock

Categoria: Etiquetas: , , Marca:

Informacoes do produto

Nome em ingles
Niraparib
Nome generico
Niraparib

Especificacoes

Especificacao
100mg*30 comprimidos
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong

Detalhes completos

Indicacoes

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mecanismo de acao

PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Farmacologia

12.1 Como funciona PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Dosagem

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Precaucoes

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Interacoes medicamentosas

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Reacoes adversas

/ [ Precaucoes(5.1)] [ Precaucoes(5.2)] [ Precaucoes(5.3)] [ Precaucoes(5.4)] [ Precaucoes(5.5)] [ Precaucoes(5.6)] 223 [ Precaucoes(5.7)] [ Precaucoes(5.8)] 6.1

Armazenamento

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，

Package Insert

Ingredients

11 AKEEGA® ADP- PARP 2-{4-[(3S)- -3- ] }-2H- 7- 4- 1:1:1 C₂₆H₃₀N₄O₅S， 510.61 g/mol

Indications

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Dosagem

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Reacoes adversas

/ [ Precaucoes(5.1)] [ Precaucoes(5.2)] [ Precaucoes(5.3)] [ Precaucoes(5.4)] [ Precaucoes(5.5)] [ Precaucoes(5.6)] 223 [ Precaucoes(5.7)] [ Precaucoes(5.8)] 6.1

Precautions

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Use in Pregnancy and Lactation

8.1 AKEEGA Como funciona[ (12.1)]，AKEEGA AKEEGA / - ， ， [ Precaucoes (5.2) (13.1)] Como funciona ，

Interacoes medicamentosas

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Clinical Pharmacology

12 12.1 Como funciona PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ， ， ， 17α- /C17,20-

Clinical Studies

14 14.1 BRCA2 (mCSPC) AKEEGA AMPLITUDE (NCT04497844) ， 696 (HRR) (HRRm) mCSPC ， 1:1 ， 200 mg 1000 mg (n=348) (n=348) 5 mg， 14 (ADT) mCSPC ， 45 6 6 ADT HRR BRCA2 CDK12

Armazenamento

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，

Avaliacoes do produto (17)

Filtro: Todas as avaliacoes
4.8★★★★★
17 avaliacoes de clientes14 compras verificadas
+o***e· ha 3 semanas
★★★★
+t***3· ha 1 meses
Compra verificada
★★★★★

Descricao

Indicacoes

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mecanismo de acao

PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Farmacologia

12.1 Como funciona PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Dosagem

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Precaucoes

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Interacoes medicamentosas

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Reacoes adversas

/ [ Precaucoes(5.1)] [ Precaucoes(5.2)] [ Precaucoes(5.3)] [ Precaucoes(5.4)] [ Precaucoes(5.5)] [ Precaucoes(5.6)] 223 [ Precaucoes(5.7)] [ Precaucoes(5.8)] 6.1

Armazenamento

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，